Drug
Erlotinib
Erlotinib: highest development phase Phase 2, developed by Astellas, United Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Astellas, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Erlotinib Hydrochloride NCT01664897 | Phase 2 | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome |
| Erlotinib NCT01247922 | Phase 2 | Ependymoma |
Latest
No recent events.
Follow Erlotinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.